Clinical Infectious Disease Studies

The overuse of antibiotics and other antimicrobial medicines has led to the global increase of antimicrobial resistance (AMR). As biopharmaceutical companies step up to address this through the development of newer, more effective therapies, they are faced with the many complexities of planning and implementing a successful infectious disease clinical trial. These obstacles include high expense, complex regulatory requirements and the increasing difficulty of finding and recruiting treatment-naïve patients.

At SPRI Clinical Trials, we have extensive experience managing these challenges in global trials for numerous indications, including HIV, HPV, HCV and HBV. Combined, our infectious disease professionals have over 65 years of experience in the design, development and execution of infectious disease clinical trials.

To learn more about SPRI’s infectious disease research capabilities, contact us today. With strategic offices in the United States (New York and North Carolina), Ukraine, Russia, Georgia and Belarus and strategic partnerships in Western Europe and Australasia, SPRI Clinical Trials is uniquely positioned to meet the challenges of international clinical trials.